ORPHA:99860
Precursor B-cell acute lymphoblastic leukemia
Also known as: B-ALL · Precursor B-cell acute lymphoblastic leukemia/lymphoma · Precursor B-cell acute lymphocytic leukemia · Precursor B-cell acute lymphocytic leukemia/lymphoma
Publications
99,595
Trials
69
Interventional, condition-specific
Researchers
1,311
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
A rare acute lymphoblastic leukemia characterized by infiltration of bone marrow and peripheral blood by small to medium-sized blast cells typically positive for the B-cell markers CD19, cCD79a, and cCD22. Predilection sites for extramedullary involvement are the central nervous system, lymph nodes, spleen, liver, and testes. Patients present with evidence of bone marrow failure (i. e. thrombocytopenia, anemia, and/or neutropenia) and variable leukocyte count, as well as lymphadenopathy, , , bone pain, and arthralgias.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0020511
- UMLS:C0349636
- NCIT:C8644
Additional Mondo synonyms (13)
B cell precursor type acute leukaemia · B cell precursor type acute leukemia · B-cell precursor type acute leukaemia · B-cell precursor type acute leukemia · B-precursor ALL · precursor B-cell acute lymphoblastic leukemia/lymphoma · precursor B-cell acute lymphocytic leukaemia · precursor B-cell acute lymphocytic leukemia · precursor B-cell acute lymphocytic leukemia/lymphoma · precursor B-lymphoblastic leukaemia · precursor B-lymphoblastic leukaemia (B-precursor ALL) · precursor B-lymphoblastic leukemia · precursor B-lymphoblastic leukemia (B-precursor ALL)
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
99,595 matched papers (66,782 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialPresent
69 matched on ClinicalTrials.gov (38 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
99,595
99,595 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
99,595 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
66,782 in the last 10 years · low confidence
Phrase hits: 99,595 · MeSH hits: 0
Who's working on it?
1,311
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01DeKoter RP9 papers · 2026
Department of Microbiology and Immunology, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada rdekoter@uwo.ca.
Papers in Europe PMC - 02Zhang L9 papers · 2026
Department of Oncology, The General Hospital of Western Theater Command, Chengdu, China.
Papers in Europe PMC - 03Iansavitchous J5 papers · 2024
Department of Microbiology and Immunology, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.
Papers in Europe PMC - 04Li Y5 papers · 2026
Department of Pediatrics, The Third Xiang-Ya Hospital of Central South University, Changsha, China.
Papers in Europe PMC - 05Sams MP5 papers · 2024
Department of Microbiology & Immunology and the Center for Human Immunology, Schulich School of Medicine & Dentistry, Western University, London, Ontario, Canada.
Papers in Europe PMC - 06Batista CR4 papers · 2024
Department of Microbiology and Immunology, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.
Papers in Europe PMC - 07Chen M4 papers · 2026
National Cancer Data Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, P.R. China.
Papers in Europe PMC - 08
- 09Li X4 papers · 2026
Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, P. R. China. lxjneuro@csu.edu.cn.
Papers in Europe PMC - 10Lim M4 papers · 2024
Department of Microbiology and Immunology, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
69
interventional trials for this specific condition
69 interventional trials matched this specific condition name; 38 currently recruiting in our sample. 1,418 trials are registered for acute lymphoblastic leukemia, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 27 July 2026
69 interventional trials — more than 73% of diseases in the trials denominator have none at all (5114 of 7003; this disease is at the 97.9th percentile).
low confidence · 97.9th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
69 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT07556757·RECRUITING·A Safety and Efficacy Study of CD-19 t-haNK in Patients With B-cell Acute Lymphoblastic Leukemia
Conditions: B-ALL · Leukemia·Matched via name phrase
- NCT04276870·RECRUITING·Orphan Indications for CD19 Redirected Autologous T Cells
Conditions: Pediatric and Young Adult Patientswith Hypodiploid or t(17;19) B-ALL · Infants With Very High Risk KMT2A B-ALL · Patients With Central Nervous System Relapse Who Did Not Receive Cranial Radiation or Bone Marrow Transplantation·Matched via name phrase
- NCT06882057·RECRUITING·Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol
Conditions: Acute Lymphoblastic Leukemia ALL · Childhood Leukemia, Acute Lymphoblastic · B Cell Acute Lymphoblastic Leukemia (B-ALL)·Matched via name phrase
- NCT06742515·RECRUITING·Blinatumomab Plus Reduced-dose Chemotherapy in Treating B-ALL
Conditions: Precursor B-Cell Acute Lymphoblastic Leukemia·Matched via name phrase
- NCT05621291·RECRUITING·A Multicenter Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-Cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymph...
Conditions: B-All · Acute Lymphoblastic Leukemia·Matched via name phrase
- NCT07502118·RECRUITING·NexCAR19 (Talikabtagene Autoleucel) in Relapsed/Refractory B-Cell Malignancies (NexCAR19)
Conditions: Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (B-ALL) · Relapsed/Refractory Non-Hodgkin Lymphoma · Diffuse Large B-Cell Lymphoma (DLBCL) · High-grade B-cell Lymphoma (HGBCL)·Matched via name phrase
- NCT06785324·RECRUITING·Study of Nutrition and Exercise in Adults Hospitalized for Treatment of Acute Lymphoblastic Leukemia (ALL)
Conditions: Philadelphia Chromosome Negative · B Cell Acute Lymphoblastic Leukemia (B-ALL) · B-ALL·Matched via name phrase
- NCT06514768·RECRUITING·JY231 (JY231) Injection for the Treatment of B-cell Acute Lymphoblastic Leukemia (B-ALL)
Conditions: B-cell Acute Lymphoblastic Leukemia (B-ALL)·Matched via name phrase
- NCT07493408·NOT YET RECRUITING·Asciminib & Standard-of-Care Integration in Maintenance Therapy for POST Allogeneic Stem Cell Transplant (Allo-HSCT) of Patient With Ph+ B-ALL or Blastic Transformed CML
Conditions: Ph+ Acute Lymphoblastic Leukemia (Ph+ALL) · Blastic Transformation of Chronic Myeloid Leukemia · Philadelphia Chromosome-positive B-cell Acute Lymphoblastic Leukemia (Ph+ B-ALL) · Haematopoietic Stem Cell Transplant, Allogeneic·Matched via name phrase
- NCT07723911·NOT YET RECRUITING·A Study of Injectable BLB101 and Blincyto® in Adult Participants With R/R CD19+ B-ALL
Conditions: Precursor B-cell Acute Lymphoblastic Leukemia·Matched via name phrase
- NCT07113496·NOT YET RECRUITING·RN1201injection for Relapsed/Refractory CD19+/BCMA+ Hematologic Malignancies
Conditions: Relapsed or Refractory B-cell Hematologic Malignancies · B-cell Acute Lymphoblastic Leukemia (B-ALL) · Multiple Myeloma (MM) · Plasmablastic Lymphoma·Matched via name phrase
- NCT06137118·RECRUITING·AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
Conditions: B-cell Acute Lymphoblastic Leukemia (B-ALL)·Matched via name phrase
- NCT07244406·RECRUITING·Assessment of Senl_B19 CAR-T Cells in Relapsed/Refractory CD19+ B-ALL
Conditions: B-ALL·Matched via name phrase
- NCT05579132·RECRUITING·A Clinical Study of MK-1045 (CN201) in People With Precursor B-cell Acute Lymphoblastic Leukemia (MK-1045-002)
Conditions: Acute Lymphoblastic Leukemia·Matched via name phrase
- NCT04318678·RECRUITING·CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)
Conditions: AML/MDS · B-ALL · T-ALL · BPDCN·Matched via name phrase
Broader category: acute lymphoblastic leukemia
1,418
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT02727803·RECRUITING·Personalized NK Cell Therapy in CBT
Conditions: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive · Acute Biphenotypic Leukemia · Acute Lymphoblastic Leukemia · Acute Lymphoblastic Leukemia in Remission·Matched via name phrase
- NCT05281809·RECRUITING·Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia
Conditions: B-Cell Lymphoma · B Acute Lymphoblastic Leukemia · Diffuse Large B Cell Lymphoma · Mantle Cell Lymphoma·Matched via name phrase
- NCT05029531·RECRUITING·Combined Immuno-chemotherapy for Patients With B-linear Acute Lymphoblastic Leukemia Diagnosed From 0 to 365 Days of Life (ALL-Baby-2021)
Conditions: Acute Lymphoblastic Leukemia, Pediatric · ALL, Infants·Matched via name phrase
- NCT07513129·RECRUITING·Venetoclax, Dexamethasone, Bortezomib, and Daratumumab For The Treatment Of Adolescent And Young Adults With Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia And T-cell Acute Lymphoblastic Lymphoma
Conditions: T-cell Acute Lymphoblastic Leukemia · Lymphoma·Matched via name phrase
- NCT07479927·RECRUITING·Telematic Cognitive Training and Mindfulness in Pediatric Patients After CAR-T Cell Therapy, Single Hematopoietic Allogeneic Transplant or Chemotherapy
Conditions: Acute Lymphoblastic Leukemia·Matched via name phrase
- NCT07356154·RECRUITING·A Study of Revumenib and Mezigdomide in People With Leukemia
Conditions: Leukemia · Acute Leukemia · Relapse Leukemia · Refractory Leukemia·Matched via name phrase
- NCT06289673·RECRUITING·Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma
Conditions: Acute Lymphoblastic Leukemia · Lymphoblastic Lymphoma · Mixed Phenotype Acute Leukemia·Matched via name phrase
- NCT06013423·RECRUITING·Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
Conditions: Acute Leukemia of Ambiguous Lineage · Acute Lymphoblastic Leukemia · Acute Myeloid Leukemia · Blastic Plasmacytoid Dendritic Cell Neoplasm·Matched via name phrase
- NCT06886074·RECRUITING·Efficacy of Short-course Blinatumomab for MRD Erradication in B-ALL
Conditions: Acute Lymphoblastic Leukemia · Measurable Residual Disease (MRD)·Matched via name phrase
- NCT07532525·RECRUITING·Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma
Conditions: Recurrent B Acute Lymphoblastic Leukemia · Recurrent B-Cell Non-Hodgkin Lymphoma · Refractory B Acute Lymphoblastic Leukemia · Refractory B-Cell Non-Hodgkin Lymphoma·Matched via name phrase
- NCT06608342·RECRUITING·Autologous Hematopoietic Stem Cell Transplantation Combined With CD19-CART Treatment of Adult High-risk Acute Lymphoblastic Leukemia
Conditions: Acute Lymphoblastic Leukemia ALL·Matched via name phrase
- NCT04888741·RECRUITING·Methods of T Cell Depletion Trial (MoTD)
Conditions: Acute Myeloid Leukemia · Acute Lymphoblastic Leukemia · Chronic Myelomonocytic Leukemia · Myelodysplastic Syndromes·Matched via name phrase
- NCT07366801·RECRUITING·Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft to Prevent Graft-versus Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Among Children With Hematologic Malignancies
Conditions: Acute Myeloid Leukemia, Relapsed · Acute Lymphoblastic Leukemia, High Risk · Acute Myeloid Leukemia, High Risk · Acute Lymphoblastic Leukemia, Relapse·Matched via name phrase
- NCT07575412·NOT YET RECRUITING·SHR2554/AZA + Overlapped Modified BUCY for High-risk/Relapsed Leukemia/MDS
Conditions: Acute Myeloid Leukemia · Acute Lymphoblastic Leukemia · MDS · Transplantation, Stem Cell·Matched via name phrase
- NCT05210907·RECRUITING·Clinical Study of Hospital-manufactured CD19 CAR-T in Children and Adolescents With Acute Lymphoblastic Leukemia
Conditions: B-cell Acute Lymphoblastic Leukemia·Matched via name phrase
Observational and natural-history studies
8 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
- NCT07637929·NOT YET RECRUITING·Non-Interventional Study of Puzol-cel for CD19-Positive Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
Conditions: Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia (r/r B-ALL)·Matched via name phrase
- NCT07422337·RECRUITING·A Multi-site Study to Evaluate the Persistence of Protective Immunity to Routine Childhood Vaccinations in Participants With B-ALL/Ly Who Have Received Blinatumomab
Conditions: B-Cell ALL · B-Cell Acute Lymphoblastic Leukaemia · B-Cell Lymphoblastic Leukemia · B-Cell Lymphoblastic Leukemia/Lymphoma·Matched via name phrase
- NCT06579469·RECRUITING·Prospective Evaluation Of Delayed Effects Of Pediatric Car T Cell Therapy
Conditions: B-ALL · Hematologic Malignancy · Solid Tumor·Matched via name phrase
- NCT06993766·NOT YET RECRUITING·The Predictability of CD19 Expression Across Primitive Cellular Fractions of Relapsed B-ALL on Outcomes of CD19-targeted CAR T-cells
Conditions: Relapsed B-ALL · CAR T-cells · CD19-directed CAR T-cell Therapy·Matched via name phrase
- NCT07048535·RECRUITING·CAR T-cell Long-Term Follow-Up, Quality of Life and Adverse Reactions
Conditions: B-Cell Acute Lymphoblastic Leukemia (B-ALL)·Matched via name phrase
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Precursor B-cell acute lymphoblastic leukemia" OR "B-ALL" OR "Precursor B-cell acute lymphoblastic leukemia/lymphoma" OR "Precursor B-cell acute lymphocytic leukemia" OR "Precursor B-cell acute lymphocytic leukemia/lymphoma" OR "B cell precursor type acute leukaemia" OR "B cell precursor type acute leukemia" OR "B-cell precursor type acute leukaemia" OR "B-cell precursor type acute leukemia" OR "B-precursor ALL" OR "precursor B-cell acute lymphocytic leukaemia" OR "precursor B-lymphoblastic leukaemia" OR "precursor B-lymphoblastic leukaemia (B-precursor ALL)" OR "precursor B-lymphoblastic leukemia" OR "precursor B-lymphoblastic leukemia (B-precursor ALL)"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Precursor B-cell acute lymphoblastic leukemia" OR "B-ALL" OR "Precursor B-cell acute lymphoblastic leukemia/lymphoma" OR "Precursor B-cell acute lymphocytic leukemia" OR "Precursor B-cell acute lymphocytic leukemia/lymphoma" OR "B cell precursor type acute leukaemia" OR "B cell precursor type acute leukemia" OR "B-cell precursor type acute leukaemia" OR "B-cell precursor type acute leukemia" OR "B-precursor ALL" OR "precursor B-cell acute lymphocytic leukaemia" OR "precursor B-lymphoblastic leukaemia" OR "precursor B-lymphoblastic leukaemia (B-precursor ALL)" OR "precursor B-lymphoblastic leukemia" OR "precursor B-lymphoblastic leukemia (B-precursor ALL)"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 69 interventional · 8 observational · 1 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"acute lymphoblastic leukemia"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
- Publication count (99595) is extremely high with unknown/missing prevalence — treat as possible over-matching, not proven research intensity
Ingested 2026-07-27T06:25:20.276Z
